Sometimes I think we all lose sight of the size of the market...

Sometimes I think we all lose sight of the size of the market Imugene has an excellent

chance of penetrating with cancer beating therapies that are proven to actually work

effectively. More to the point – with the potential to reduce invasive chemotherapy and

radiotherapy treatment, as well as surgery … giving people the opportunity to overcome

their cancer. Imugene is far more than simply a share currently valued at under 9¢.

NB: All figures are quoted from a range of sources – and estimates do vary, sometimes

quite considerably.

Globally there are approximately 19 million cases of cancer diagnosed each year at the

moment, but this is projected to grow to over 29 million annually within the next 10 years.

There were 9.5 million cancer deaths globally last year.

Breast Cancer represents 12.5%

Lung Cancer represents 12.2%

Colorectal Cancer represents 11%

Let’s just skim the surface re. the amounts of money being spent in the area of medical

treatment for those who are unfortunate enough to contract cancer. Figures are global.

All expressed in $US Billions.

Solid Tumour Cancer Treatment Market Size this year: $186 Billion

Solid Tumour Cancer Treatment Market Size projected for 2032: $532 Billion

Solid Tumour Cancer Treatment Market Size 2022-2032: $3,656 Billion

Cancer Drugs Market Size this year: over $143 Billion

Cancer Drugs Market Size projected by 2029: over $420 Billion

The Top Pharmaceutical Companies by Oncology Sales last year:

F. Hoffman-La Roche: $30 Billion

Cellgene: $20 Billion

AstraZenica: $14 Billion

Bristol Myers Squibb: $14 Billion

Pfizer: $14 Billion

Johnson & Johnson: $13 Billion

Merck: $13 Billion

Novartis: $10 Billion

So, the corollary of Imugene achieving innovation and success could have very large

effects – even if the market penetration percentage is only in single figures. The value is

very large … as well as the people it could help.

I feel sure that shareholders will be rewarded for both patience and confidence in

Imugene – in the near future, we’ll look back and laugh at the mid-2023 share price.